Abstract: A method for motion correction of Magnetic Resonance (MR) images is provided. The method includes acquiring a k-space dataset for an object using an MR scanner, detecting or identifying corrupted k-space data from the acquired k-space dataset, extracting the corrupted k-space data from the acquired k-space dataset, recovering the corrupted k-space data, combining uncorrupted k-space data of the acquired k-space dataset with the recovered k-space data to form a full k-space dataset, and reconstructing an image for the object based on the full k-space dataset. A magnetic resonance imaging system for correcting corrupted k-space data of an entire k-space dataset is also provided.

Abstract: Small molecule inhibitors (SMIs) of the Prolactin receptor, pharmaceutical compositions of the SMIs, and methods for treating patients suffering from disorders characterized increased expression or excitation of the Prolactin receptor, including breast cancer, prostate cancer and nociceptive pain disorders such as migraine headache, by administering pharmaceutical compositions of SMIs are provided.

Abstract: Controlled release hydrogel formulations of one or more simvastatin metabolites 3?-hydroxy simvastatin (hSV), 6?-exomethylene simvastatin (eSV), 3?,5?-dihydrodiol simvastatin, 3?,5?-dihydrodiol simvastatin (dSV), simvastatin-beta-hydroxy acid (SVA), and methods for the treatment of patients suffering from injured or degenerating substantially avascular cartilaginous tissue.

Abstract: A method of reducing the incidence of hypoglycemia in an insulin-requiring subject is provided. The subject is administered insulin either via regular doses of insulin or via continuous subcutaneous infusion. The method involves administering to the subject C-peptide in conjunction with at least a portion of the administered insulin, where the insulin dosage is not reduced from the subject’s regular dosage as a result of the administration of C-peptide.

Abstract: A system for modulating operation of an organ in real time by controlling illumination of one or more light components is provided. The system includes an external device comprising a processing unit and a power supply configured to transmit stimulation parameters, a wireless implantable device comprising, a sensor configured to detect, in real time, activity data from a tissue cluster of an organ, a stimulator including a plurality of light components corresponding to at least a first wavelength and a second wavelength and a flexible elastomer coupled to the plurality of light components, and a transceiver configured to transmit the activity data to the external device, wherein the stimulator is configured to illuminate, based on the stimulation parameters, one of the plurality of light components coupled to the flexible elastomer, wherein the processing unit is configured to update the stimulation parameters based on the activity data.

Abstract: A method for k-space registration is provided. The method of k-space registration includes receiving a first partial k-space dataset for an object and a second partial k-space dataset for the object, selecting the first partial k-space dataset as a reference, selecting feature for estimating a transformation matrix for transforming k-space data, estimating a transformation matrix based on the feature of entire or part of the first partial k-space dataset and the feature of the second partial k-space dataset corresponding to the entire or part of the first partial k-space dataset, correcting the second partial k-space dataset based on the transformation matrix, and obtaining the corrected second partial k-space dataset. The present method is further used for partial Fourier reconstruction.

Abstract: A device and method including at least one electrochemical aptamer sensor for small sample volume sensing. The device (100) includes at least one substrate (110) that defines a microfluidic feature (118) having a defined volume. At least one electrochemical aptamer sensor (120), including an electrode (122) associated with a plurality of aptamers (124), is carried by the substrate and is in fluid communication with the defined volume. The defined volume is capable of containing less than 30 ?L of a sample fluid when the defined volume is filled with the sample fluid. Additionally, or alternatively, the volume of the sample fluid in ?L is equal to C * the surface area of the electrode in cm2 that is associated with the plurality of aptamers/concentration of the target analyte in ?M; and C has a value chosen from less than 4, less than 0.4, less than 0.04, and less than 0.004.

Abstract: A device and method for detecting the presence of, or measuring the amount or concentration of, at least one analyte in a sample fluid, where the device includes a dissolvable material, and a plurality of aptamers disposed in and/or on the dissolvable material, and where one or more aptamers of the plurality of aptamers (1) are capable of binding at least one analyte, and (2) have at least one redox tag attached thereto.

Abstract: A method is provided for prognosing a risk in a patient diagnosed with a premalignant lesion of the breast of the lesion progressing to breast cancer, the method comprising: providing a tissue sample of the premalignant lesion; detecting one or more variants of Osteopontin (OPN) selected from OPN-a, OPN-b and OPN-c in the sample; and prognosing an elevated risk of the lesion progressing to breast cancer if OPN-b and/or OPN-c is detected and/or OPN-a is elevated above normal levels in the tissue sample. Methods of assessing risk of death from breast cancer, methods of treatment, and kits for prognosis are also provided herein.

Abstract: A method of non-invasively diagnosing and treating a cancer characterized by high surface phosphatidylserine (PS) expression in a subject in need thereof is provided, the method including: obtaining a liquid biological sample from the subject; detecting a presence of cancer-secreted soluble phosphorylated Heat shock protein-70 (Hsp70) in the liquid biological sample; diagnosing the subject with a cancer characterized by high surface PS expression when cancer-secreted soluble phosphorylated Hsp70 is present in the liquid biological sample; and administering an anti-cancer therapy targeted to high surface PS expressing-cancers to the diagnosed subject. Also provided is a method for monitoring therapeutic efficacy of a treatment in a subject with a cancer characterized by high surface PS expression.

Abstract: A laminate which can serve as either a smart window or a smart mirror is formed using first and second substrates coated with transparent first and second electrodes which are separated by foraminous layer and a third grid-like linear electrode insulated from the first and second electrodes. The foraminous layer includes spacers defining a cell space which is filled with a colloidal ink having first and second particles. The first particles have a positive charge and a first color and second particles having a negative charge and a second color different from the first color. By altering the voltages of the first, second and third electrodes, one can achieve different light transmission characteristics which, for example, can alter the color temperature of the light transmitted through the laminate or enhance reflective colors.

Abstract: A rotating detonation combustor includes a nozzle coupled to the combustor body at or near the exhaust opening to choke the exhaust opening. A rotating detonation combustor may include a diverting plate positioned radially inward of the inlet annulus and inlet channels for diverting flow of a mixture in an axial direction. A rotating detonation combustor may include a combustor body including an outer shell at least partially defining a detonation combustion chamber and extending axially from a base toward an exhaust opening of the detonation combustion chamber. The base defines a passageway in fluid communication with the detonation combustion chamber and includes an inlet annulus for axially directing a second fluid into the passageway and a plurality of inlet channels for radially directing a third fluid into at least one of the passageway or the detonation combustion chamber, and the detonation combustion chamber is free of any inner body.

Abstract: A method for slowing the progression of amyotrophic lateral sclerosis (ALS) in an adult subject in need thereof is provided herein, the method including inhibiting motor neuron degeneration by administering to the subject a modified adeno-associated virus (AAV) vector having a recombinant AAV (rAAV)-based genome with an AAV backbone, a control element, and a ciliary neurotrophic factor receptor alpha (CNTFR?) cDNA insert, wherein the modified AAV vector is engineered to direct enhanced skeletal muscle expression of CNTFR?.

Abstract: Controlled release hydrogel formulations of one or more simvastatin metabolites 3?-hydroxy simvastatin (hSV), 6?-exomethylene simvastatin (eSV), 3?,5?-dihydrodiol simvastatin, 3?,5?-dihydrodiol simvastatin (dSV), simvastatin-beta-hydroxy acid (SVA), and methods for the treatment of patients suffering from injured or degenerating substantially avascular cartilaginous tissue.

Abstract: A biomedical implant (16, 18) is formed from magnesium (Mg) single crystal (10). The biomedical implant (16, 18) may be biodegradable. The biomedical implant (16, 18) may be post treated to control the mechanical properties and/or corrosion rate thereof said Mg single crystal (10) without changing the chemical composition thereof. A method of making a Mg single crystal (10) for biomedical applications includes filling a single crucible (12) with more than one chamber with polycrystalline Mg, melting at least a portion of said polycrystalline Mg, and forming more than one Mg single crystal (10) using directional solidification.

Abstract: A storage solution for packed red blood cells is disclosed where the solution is alkaline and has a viscosity at 4° C. greater than about 20 millipascal seconds. In one embodiment, the storage solution comprises from about 0.1 percent to about 10 percent of hydroxy-propyl-methyl-cellulose. In another embodiment, the storage solution has a pH greater than about 8.

Abstract: Targeted drug delivery systems comprising a therapeutic agent solubilized with undecylenic acid (UA)-based nanocarrier vesicles that may be polymerized or provided as an mPEG ester are provided to achieve targeted delivery of, for example, ROS-activated cytotoxic agents to cancer cells exhibiting high levels of ROS. Methods utilizing photodynamic and sonodynamic generation of ROS to enhance targeted delivery are also provided.

Abstract: A method of simultaneously outputting a plurality of cavitation types on a digital image is provided. The method includes detecting acoustic emissions corresponding to the plurality of cavitation types, the plurality of cavitation types including at least some combination of linear scatter, stable cavitation, and inertial cavitation, generating, based on the acoustic emissions, a two-dimensional color map of the plurality of cavitation types on the digital image, the two-dimensional color map includes a first acoustic emission corresponding to linear scatter or stable cavitation and a second acoustic emission corresponding to linear scatter or inertial cavitation, and outputting on the digital image, displayed on the display of the computing device, the two-dimensional color map of the plurality of cavitation types.

Abstract: Decellularized matrix microspheres comprising a polymeric material and a donor tissue are provided. Also disclosed are structures containing a plurality of decellularized matrix microspheres incorporating a first polymer and a donor tissue; and a second polymer, wherein the decellularized matrix microspheres and the second polymer are in the form of a filament. Methods of treating a tissue injury employing the matrix microspheres and structures described as well as their methods of manufacture are also provided.

Abstract: A remote health care apparatus is disclosed that incorporates a drone device and a health kit. The drone device includes one or more communication devices, and the drone device is capable of two-way auditory and visual communication. The health kit is capable of being transported by the drone device and can be detached from the drone device. In one embodiment, the health kit contains one or more medical devices selected from the group consisting of biometric measuring devices, specimen collection devices and lab testing tools.